Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:The role of cyclooxygenase-2 in the malignant tissue and possible applicability of cyclooxygenase-2 inhibitors in the therapy of cancer
Authors:ID Legan, Mateja (Author)
Files:.pdf PDF - Presentation file, download (205,37 KB)
MD5: D29F325E25EC16D5D15056F9C1790F95
 
Language:English
Typology:1.02 - Review Article
Organization:Logo OI - Institute of Oncology
Abstract:Cyclooxygenase-2 (COX 2), an inducible prostaglandin (PG) synthase, is elevated in many types of malignant and pre-malignant tissues. This enzyme is localized in neoplastic (epithelial) cells, microvascular endothelial cells, and stromal fibroblasts. Through the released PG it enhances carcinogenesis with increasing angiogenesis, inhibiting apoptosis, activating matrix metalloproteinases, suppressing of cell mediated antitumor immune response andprotection against damage by cytotoxic agents. Evidences from in vitro studies, studies on animal models as well as first clinical outcomes suggest that the inhibition of COX 2 may suppress carcinogenesis by affecting a numberof pathways: inhibiting angiogenesis, invasiveness of tumors and promoting apoptosis. References forecast that COX 2 inhibitors, mostly COX 2 selective inhibitors, may get a role in the therapy of cancer as an adjuvant therapy or as an co-chemotherapeutic agent. The purpose of the present articleis to summarize the most important facts about the role of COX 2 in themalignant tissue and discuss possible ways for potential therapeutic place of COX 2 inhibitors in clinical practice.
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2003
Publisher:Association of Radiology and Oncology
Year of publishing:2003
Number of pages:str. 187-194
Numbering:Letn. 37, št. 3
Source:Ljubljana
PID:20.500.12556/DiRROS-18109-3900721c-c6b4-8b29-16e1-303f161c6fbc New window
UDC:616-006
ISSN on article:1318-2099
COBISS.SI-ID:17000153 New window
Copyright:by Authors
Note:BSDOCID101592;
Publication date in DiRROS:06.02.2024
Views:435
Downloads:97
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Title:Vloga ciklooksigenaze-2 v malignem tkivu in možnosti uporabe njenih zaviralcev v zdravljenju raka
Abstract:Encim ciklooksigenaza-2 je inducibilna prostaglandinska sintaza. Njeno povečano izražanje so opisali v številnih premalignih in malignih tkivih. Preko povečanega sproščanja prostaglandinov pospešuje karcinogenezo, tako da pospeši tumorsko angiogenezo, zavira apoptozo, aktivira matriksne metaloproteinaze. Zavira tudi celično posredovan antitumorski imunski odgovor in ščiti pred poškodbami s citotoksičnimi učinkovinami. Cikloosigenaza-2 je lokalizirana v neoplastičnih epitelijskih celicah, endotelijskih celicah novonastalega tumorskega žilja, v fibroblastih in vnetnih celicah tumorske strome. Dokazi iz študij in vitro, raziskave na živalskih modelih ter prvi klinični rezultati kažejo, da zaviralci COX-2 lahko upočasnijo karcinogenezo zzaviranjem angiogeneze, zmanjšanjem invazivnosti tumorja in pospeševanje apoptoze tumorskih celic. Rezultati nakazujejo možno in zelo verjetno vlogo zaviralcev COX-2, predvsem selektivnih zaviralcev COX-2, v zdravljenju raka kot dodatna (adjuvantna) terapija, oz. so-kemoterapevtik, tako v primarni preventivi, zdravljenju kot tudi zaščiti pred ponovitvijo bolezni. Namen preglednega članka je predstaviti spoznanja o vlogi ciklooksigenaze-2 v malignem tkivu ter poiskati terapevtsko mesto zaviralcev COX-2 v klinični praksi.


Back